Evidence map›Paper›PMID 42675812›Full record

ReviewCancer2026

GPRC5D-targeting bispecific and trispecific antibodies in multiple myeloma: Current evidence and emerging strategies.

Darren Pan, Anupama Kumar, Jodi J Lipof, Alfred Chung, Jeffrey L Wolf, Thomas G Martin, Shagun Arora, Peter H Sayre, Ajai Chari

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Darren PanDepartment of Medicine, University of California, San Francisco, California, USA.
Anupama KumarDepartment of Medicine, University of California, San Francisco, California, USA.
Jodi J LipofDepartment of Medicine, University of California, San Francisco, California, USA.
Alfred ChungDepartment of Medicine, University of California, San Francisco, California, USA.
Jeffrey L WolfDepartment of Medicine, University of California, San Francisco, California, USA.
Thomas G MartinDepartment of Medicine, University of California, San Francisco, California, USA.ORCID https://orcid.org/0000-0003-1752-5092
Shagun AroraDepartment of Medicine, University of California, San Francisco, California, USA.
Peter H SayreDepartment of Medicine, University of California, San Francisco, California, USA.
Ajai ChariDepartment of Medicine, University of California, San Francisco, California, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

G-protein-coupled receptor class C group 5 member D (GPRC5D) has emerged as a crucial immunotherapy target in relapsed/refractory multiple myeloma. Although the T-cell-engaging bispecific antibody talquetamab is currently the only approved anti-GPRC5D therapy, numerous promising agents are undergoing clinical evaluation. While anti-GPRC5D chimeric antigen receptor T cells show potential, this review focuses specifically on T-cell-engaging bispecific and trispecific antibodies. We highlight how GPRC5D differs clinically from B-cell maturation antigen, explore mechanisms of resistance, discuss novel therapeutic strategies including combination regimens and talquetamab as bridging therapy to chimeric antigen receptor T cells, and review key investigational T-cell engagers currently in development.

Indexed as

Antibodies, BispecificMultiple MyelomaReceptors, G-Protein-CoupledAnimalsHumansImmunotherapyT-LymphocytesAntibodies, BispecificGPRC5D protein, humanReceptors, G-Protein-CoupledbridgingCAR‐T cellscombination therapyGPRC5Dimmunotherapyrelapsed refractory multiple myelomaT‐cell engagers

Identifiers

PMID42675812
PMCPMC13530427

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.